NCT06517732View on ClinicalTrials.gov

Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

RecruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

June 28, 2026

Study Completion Date

June 28, 2026

Conditions

Hidradenitis Suppurativa

Interventions

OTHER

Secukinumab

This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Trial Locations (20)

107076

RECRUITING

Novartis Investigative Site, Moscow

119049

RECRUITING

Novartis Investigative Site, Moscow

119881

RECRUITING

Novartis Investigative Site, Moscow

123182

RECRUITING

Novartis Investigative Site, Moscow

129110

RECRUITING

Novartis Investigative Site, Moscow

197022

RECRUITING

Novartis Investigative Site, Saint Petersburg

236016

RECRUITING

Novartis Investigative Site, Kaliningrad

236029

RECRUITING

Novartis Investigative Site, Kaliningrad

300053

RECRUITING

Novartis Investigative Site, Tula

350020

RECRUITING

Novartis Investigative Site, Krasnodar

355020

RECRUITING

Novartis Investigative Site, Stavropol

410028

RECRUITING

Novartis Investigative Site, Saratov

420012

RECRUITING

Novartis Investigative Site, Kazan'

426039

RECRUITING

Novartis Investigative Site, Izhevsk

440052

RECRUITING

Novartis Investigative Site, Penza

443079

RECRUITING

Novartis Investigative Site, Samara

450010

RECRUITING

Novartis Investigative Site, Ufa

603950

RECRUITING

Novartis Investigative Site, Nizhny Novgorod

650025

RECRUITING

Novartis Investigative Site, Kemerovo

677000

RECRUITING

Novartis Investigative Site, Yakutsk

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

All Listed Sponsors

lead

Novartis Pharmaceuticals

INDUSTRY